IDEAS home Printed from https://ideas.repec.org/a/spr/pharmo/v4y2020i3d10.1007_s41669-019-00175-w.html
   My bibliography  Save this article

Are Published Health Economic Models for Chronic Hepatitis B Appropriately Capturing the Benefits of HBsAg Loss? A Systematic Literature Review

Author

Listed:
  • Peter Wigfield

    (Ingress-health Nederland)

  • Urbano Sbarigia

    (Janssen Pharmaceutica)

  • Mahmoud Hashim

    (Ingress-health Nederland)

  • Talitha Vincken

    (Ingress-health Nederland)

  • Bart Heeg

    (Ingress-health Nederland)

Abstract

Objectives Sustained hepatitis B surface antigen (HBsAg) loss or ‘functional cure’ (FC) is considered an optimal treatment endpoint by international clinical guidelines for chronic hepatitis B (CHB), yet rarely is this achieved with current standard of care (SoC). This leads to an under-reporting of FC in clinical trials, observational studies and health economic (HE) models. This paper systematically identifies and assesses how FC is incorporated in published HE models of CHB. Methods A systematic literature review was conducted in PubMed and Embase (conducted February 2019) to review how HBsAg loss is captured in HE models. The following items were extracted: rate of (and transition probabilities to) HBsAg loss, HBsAg loss health state costs, and HBsAg loss health state utilities. Results Sixty-five economics evaluations were identified, and

Suggested Citation

  • Peter Wigfield & Urbano Sbarigia & Mahmoud Hashim & Talitha Vincken & Bart Heeg, 2020. "Are Published Health Economic Models for Chronic Hepatitis B Appropriately Capturing the Benefits of HBsAg Loss? A Systematic Literature Review," PharmacoEconomics - Open, Springer, vol. 4(3), pages 403-418, September.
  • Handle: RePEc:spr:pharmo:v:4:y:2020:i:3:d:10.1007_s41669-019-00175-w
    DOI: 10.1007/s41669-019-00175-w
    as

    Download full text from publisher

    File URL: http://link.springer.com/10.1007/s41669-019-00175-w
    File Function: Abstract
    Download Restriction: no

    File URL: https://libkey.io/10.1007/s41669-019-00175-w?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. David Moher & Alessandro Liberati & Jennifer Tetzlaff & Douglas G Altman & The PRISMA Group, 2009. "Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement," PLOS Medicine, Public Library of Science, vol. 6(7), pages 1-6, July.
    2. Drummond, Michael F. & Sculpher, Mark J. & Claxton, Karl & Stoddart, Greg L. & Torrance, George W., 2015. "Methods for the Economic Evaluation of Health Care Programmes," OUP Catalogue, Oxford University Press, edition 4, number 9780199665884.
    3. Paul Kind & Geoffrey Hardman & Susan Macran, 1999. "UK population norms for EQ-5D," Working Papers 172chedp, Centre for Health Economics, University of York.
    4. Elizabeth Arnold & Yong Yuan & Uchenna Iloeje & Greg Cook, 2008. "Cost-effectiveness analysis of entecavir versus lamivudine in the first-line treatment of Australian patients with chronic hepatitis B," Applied Health Economics and Health Policy, Springer, vol. 6(4), pages 231-246, October.
    Full references (including those not matched with items on IDEAS)

    Citations

    Blog mentions

    As found by EconAcademics.org, the blog aggregator for Economics research:
    1. Rita Faria’s journal round-up for 14th September 2020
      by Rita Faria in The Academic Health Economists' Blog on 2020-09-14 11:00:07

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Bishal Mohindru & David Turner & Tracey Sach & Diana Bilton & Siobhan Carr & Olga Archangelidi & Arjun Bhadhuri & Jennifer A. Whitty, 2020. "Health State Utility Data in Cystic Fibrosis: A Systematic Review," PharmacoEconomics - Open, Springer, vol. 4(1), pages 13-25, March.
    2. Dina Jankovic & Pedro Saramago Goncalves & Lina Gega & David Marshall & Kath Wright & Meena Hafidh & Rachel Churchill & Laura Bojke, 2022. "Cost Effectiveness of Digital Interventions for Generalised Anxiety Disorder: A Model-Based Analysis," PharmacoEconomics - Open, Springer, vol. 6(3), pages 377-388, May.
    3. Nadia Pillai & Mark Dusheiko & Bernard Burnand & Valérie Pittet, 2017. "A systematic review of cost-effectiveness studies comparing conventional, biological and surgical interventions for inflammatory bowel disease," PLOS ONE, Public Library of Science, vol. 12(10), pages 1-22, October.
    4. Darcy M. Anderson & Ryan Cronk & Donald Fejfar & Emily Pak & Michelle Cawley & Jamie Bartram, 2021. "Safe Healthcare Facilities: A Systematic Review on the Costs of Establishing and Maintaining Environmental Health in Facilities in Low- and Middle-Income Countries," IJERPH, MDPI, vol. 18(2), pages 1-22, January.
    5. Antonio Ahumada-Canale & Camila Quirland & Francisco J. Martinez-Mardones & José Cristian Plaza-Plaza & Shalom Benrimoj & Victoria Garcia-Cardenas, 2019. "Economic evaluations of pharmacist-led medication review in outpatients with hypertension, type 2 diabetes mellitus, and dyslipidaemia: a systematic review," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 20(7), pages 1103-1116, September.
    6. Susanne Mayer & Noemi Kiss & Agata Łaszewska & Judit Simon, 2017. "Costing evidence for health care decision-making in Austria: A systematic review," PLOS ONE, Public Library of Science, vol. 12(8), pages 1-18, August.
    7. Nystrand, Camilla & Gebreslassie, Mihretab & Ssegonja, Richard & Feldman, Inna & Sampaio, Filipa, 2021. "A systematic review of economic evaluations of public health interventions targeting alcohol, tobacco, illicit drug use and problematic gambling: Using a case study to assess transferability," Health Policy, Elsevier, vol. 125(1), pages 54-74.
    8. Henriette Busk & Ulrik Sidenius & Line Planck Kongstad & Sus Sola Corazon & Christina Bjørk Petersen & Dorthe Varning Poulsen & Patrik Karlsson Nyed & Ulrika Karlsson Stigsdotter, 2022. "Economic Evaluation of Nature-Based Therapy Interventions—A Scoping Review," Challenges, MDPI, vol. 13(1), pages 1-19, May.
    9. Ahmed Ramadan Shokry Shahat & Giulia Greco, 2021. "The Economic Costs of Childhood Disability: A Literature Review," IJERPH, MDPI, vol. 18(7), pages 1-25, March.
    10. Miriam Kasztura & Aude Richard & Nefti-Eboni Bempong & Dejan Loncar & Antoine Flahault, 2019. "Cost-effectiveness of precision medicine: a scoping review," International Journal of Public Health, Springer;Swiss School of Public Health (SSPH+), vol. 64(9), pages 1261-1271, December.
    11. Zartashia Ghani & Johan Jarl & Johan Sanmartin Berglund & Martin Andersson & Peter Anderberg, 2020. "The Cost-Effectiveness of Mobile Health (mHealth) Interventions for Older Adults: Systematic Review," IJERPH, MDPI, vol. 17(15), pages 1-13, July.
    12. Mina Bahrampour & Joshua Byrnes & Richard Norman & Paul A. Scuffham & Martin Downes, 2020. "Discrete choice experiments to generate utility values for multi-attribute utility instruments: a systematic review of methods," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 21(7), pages 983-992, September.
    13. Bromley, Hannah L. & Petrie, Dennis & Mann, G.Bruce & Nickson, Carolyn & Rea, Daniel & Roberts, Tracy E., 2019. "Valuing the health states associated with breast cancer screening programmes: A systematic review of economic measures," Social Science & Medicine, Elsevier, vol. 228(C), pages 142-154.
    14. Peter J. Neumann & David D. Kim & Thomas A. Trikalinos & Mark J. Sculpher & Joshua A. Salomon & Lisa A. Prosser & Douglas K. Owens & David O. Meltzer & Karen M. Kuntz & Murray Krahn & David Feeny & An, 2018. "Future Directions for Cost-effectiveness Analyses in Health and Medicine," Medical Decision Making, , vol. 38(7), pages 767-777, October.
    15. Valentin Brodszky & Zsuzsanna Beretzky & Petra Baji & Fanni Rencz & Márta Péntek & Alexandru Rotar & Konstantin Tachkov & Susanne Mayer & Judit Simon & Maciej Niewada & Rok Hren & László Gulácsi, 2019. "Cost-of-illness studies in nine Central and Eastern European countries," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 20(1), pages 155-172, June.
    16. Spencer, Anne & Rivero-Arias, Oliver & Wong, Ruth & Tsuchiya, Aki & Bleichrodt, Han & Edwards, Rhiannon Tudor & Norman, Richard & Lloyd, Andrew & Clarke, Philip, 2022. "The QALY at 50: One story many voices," Social Science & Medicine, Elsevier, vol. 296(C).
    17. Banke-Thomas, Aduragbemi & Aberjirinde, Ibukun-Oluwa & Ayomoh, Francis Ifeanyi & Banke-Thomas, Oluwasola & Eboreime, Ejemai Amaize & Ameh, Charles, 2020. "The cost of maternal health services in low-income and middle-income countries from a provider's perspective: a systematic review," LSE Research Online Documents on Economics 104344, London School of Economics and Political Science, LSE Library.
    18. Jason R. Guertin & Blanchard Conombo & Raphaël Langevin & Frédéric Bergeron & Anne Holbrook & Brittany Humphries & Alexis Matteau & Brian J. Potter & Christel Renoux & Jean-Éric Tarride & Madelein, 2020. "A Systematic Review of Methods Used for Confounding Adjustment in Observational Economic Evaluations in Cardiology Conducted between 2013 and 2017," Medical Decision Making, , vol. 40(5), pages 582-595, July.
    19. Salah Ghabri & Laurent Lam & François Bocquet & Hans-Martin Spath, 2020. "Systematic Literature Review of Economic Evaluations of Biological Treatment Sequences for Patients with Moderate to Severe Rheumatoid Arthritis Previously Treated with Disease-Modifying Anti-rheumati," PharmacoEconomics, Springer, vol. 38(5), pages 459-471, May.
    20. Cochrane, M. & Watson, P.M. & Timpson, H. & Haycox, A. & Collins, B. & Jones, L. & Martin, A. & Graves, L.E.F., 2019. "Systematic review of the methods used in economic evaluations of targeted physical activity and sedentary behaviour interventions," Social Science & Medicine, Elsevier, vol. 232(C), pages 156-167.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:pharmo:v:4:y:2020:i:3:d:10.1007_s41669-019-00175-w. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.